Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Viking Therapeutics, Inc. (VKTX) had Consolidated Net Income/Loss of $-158.32M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-158.32M |
|
-- |
|
-- |
|
$164.12M |
|
$-164.12M |
|
$5.80M |
|
$-158.32M |
|
$-158.32M |
|
$-158.32M |
|
$-158.32M |
|
|
Consolidated Net Income/Loss |
$-158.32M |
$-158.32M |
|
$-164.12M |
|
$-165.33M |
|
115.57M |
|
115.57M |
|
$-1.37 |
|
$-1.37 |
|
| Balance Sheet Financials | |
$608.21M |
|
-- |
|
$0.03M |
|
$608.24M |
|
$106.33M |
|
-- |
|
-- |
|
$106.33M |
|
$501.92M |
|
$501.92M |
|
$501.92M |
|
115.89M |
|
| Cash Flow Statement Financials | |
$-113.98M |
|
$54.19M |
|
$12.08M |
|
$165.81M |
|
$118.12M |
|
$-47.69M |
|
$10.34M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.72 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-113.98M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-31.54% |
|
-31.54% |
|
-26.03% |
|
-31.54% |
|
$4.33 |
|
$-0.99 |
|
$-0.99 |
|